Peter Herhaus

1.1k total citations
27 papers, 573 citations indexed

About

Peter Herhaus is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peter Herhaus has authored 27 papers receiving a total of 573 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 10 papers in Pathology and Forensic Medicine and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peter Herhaus's work include Lymphoma Diagnosis and Treatment (10 papers), Chemokine receptors and signaling (9 papers) and Immunotherapy and Immune Responses (5 papers). Peter Herhaus is often cited by papers focused on Lymphoma Diagnosis and Treatment (10 papers), Chemokine receptors and signaling (9 papers) and Immunotherapy and Immune Responses (5 papers). Peter Herhaus collaborates with scholars based in Germany, Austria and United States. Peter Herhaus's co-authors include Hans‐Jürgen Wester, Ulrich Keller, Andreas K. Buck, Constantin Lapa, Markus Schwaiger, Tibor Vág, Malte Kircher, Margret Schottelius, Rudolf A. Werner and Johannes Ettl and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cell Death and Differentiation.

In The Last Decade

Peter Herhaus

23 papers receiving 569 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Herhaus Germany 10 355 163 146 113 101 27 573
Julien Lazarovici France 10 435 1.2× 70 0.4× 189 1.3× 335 3.0× 99 1.0× 36 684
Deniz Şahin Türkiye 12 269 0.8× 133 0.8× 125 0.9× 378 3.3× 48 0.5× 52 594
Siobhan Ng Australia 12 355 1.0× 169 1.0× 161 1.1× 77 0.7× 119 1.2× 33 708
Dave Yamauchi United States 16 320 0.9× 433 2.7× 68 0.5× 192 1.7× 89 0.9× 35 713
Guillaume Manson France 10 369 1.0× 37 0.2× 156 1.1× 148 1.3× 41 0.4× 17 465
Stefan Habringer Germany 10 172 0.5× 45 0.3× 61 0.4× 91 0.8× 104 1.0× 19 351
Vittorio Silingardi Italy 12 342 1.0× 85 0.5× 87 0.6× 202 1.8× 115 1.1× 28 619
Khalil Saleh France 12 357 1.0× 50 0.3× 81 0.6× 70 0.6× 84 0.8× 53 523
Kensei Nakata Japan 14 232 0.7× 72 0.4× 52 0.4× 55 0.5× 126 1.2× 30 506
Joyce Varughese United States 15 327 0.9× 71 0.4× 46 0.3× 51 0.5× 203 2.0× 21 628

Countries citing papers authored by Peter Herhaus

Since Specialization
Citations

This map shows the geographic impact of Peter Herhaus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Herhaus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Herhaus more than expected).

Fields of papers citing papers by Peter Herhaus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Herhaus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Herhaus. The network helps show where Peter Herhaus may publish in the future.

Co-authorship network of co-authors of Peter Herhaus

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Herhaus. A scholar is included among the top collaborators of Peter Herhaus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Herhaus. Peter Herhaus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Werner, Rudolf A., Alexander Haug, Christian Buske, et al.. (2024). CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges. Nuklearmedizin - NuclearMedicine. 63(2). 57–61. 2 indexed citations
4.
Bröckelmann, Paul J., Peter Herhaus, Julia Meißner, et al.. (2023). Fertility and Gonadal Function after First-Line Treatment with Nivolumab-AVD in Hodgkin Lymphoma Patients: An Analysis from the Phase II GHSG Nivahl Trial. Blood. 142(Supplement 1). 4456–4456.
5.
Goetze, Thorsten Oliver, Alexander Stein, Sylvie Lorenzen, et al.. (2023). Ramucirumab beyond progression plus TAS‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy. International Journal of Cancer. 153(10). 1726–1733. 5 indexed citations
6.
Bröckelmann, Paul J., Peter Herhaus, Julia Meißner, et al.. (2023). Quality of Life with Nivolumab and AVD First-Line Treatment in Hodgkin Lymphoma: Patient-Reported Outcomes from the Phase II GHSG Nivahl Trial. Blood. 142(Supplement 1). 1710–1710.
7.
8.
Kraus, Sabrina, Malte Kircher, Alexander Dierks, et al.. (2022). Reduced splenic uptake on 68Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis. Theranostics. 12(13). 5986–5994. 9 indexed citations
9.
Koch, Katrin, Lena Oßwald, Katharina S. Götze, et al.. (2022). Letermovir Prophylaxis for CMV Reactivation in Allogeneic Stem Cell Recipients: A Retrospective Single Center Analysis. Anticancer Research. 42(11). 5431–5441. 3 indexed citations
10.
Menzel, H, Ulrich Keller, Katharina S. Götze, et al.. (2022). Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis. Annals of Hematology. 101(6). 1311–1319. 5 indexed citations
11.
Lewis, Richard, Stefan Habringer, Malte Kircher, et al.. (2021). Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients. EJNMMI Research. 11(1). 77–77. 17 indexed citations
12.
Orberg, Erik Thiele, Andreas Hiergeist, Jinling Xue, et al.. (2021). Longitudinal Analysis of Gut Bacteriome, Mycobiome, Virome and Metabolome in Allogeneic Stem Cell Transplantation Reveals Susceptibility for Acute Graft-Versus-Host Disease. Blood. 138(Supplement 1). 332–332. 1 indexed citations
13.
Herhaus, Peter, Jana Lipková, Igor Yakushev, et al.. (2020). CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma. Journal of Nuclear Medicine. 61(12). 1765–1771. 37 indexed citations
14.
Maurer, Sabine, Peter Herhaus, Heribert Hänscheid, et al.. (2019). Side Effects of CXC-Chemokine Receptor 4–Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation. Journal of Nuclear Medicine. 60(10). 1399–1405. 44 indexed citations
15.
Kircher, Malte, Peter Herhaus, Margret Schottelius, et al.. (2018). CXCR4-directed theranostics in oncology and inflammation. Annals of Nuclear Medicine. 32(8). 503–511. 102 indexed citations
16.
Vág, Tibor, Katja Steiger, Andreas Roßmann, et al.. (2018). PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma. EJNMMI Research. 8(1). 90–90. 33 indexed citations
17.
Herhaus, Peter, Stefan Habringer, Tibor Vág, et al.. (2017). Response assessment with the CXCR4-directed positron emission tomography tracer [68Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavities. EJNMMI Research. 7(1). 51–51. 25 indexed citations
18.
Habringer, Stefan, Constantin Lapa, Peter Herhaus, et al.. (2017). Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics. Theranostics. 8(2). 369–383. 79 indexed citations
19.
Vág, Tibor, Carlos Gerngroß, Peter Herhaus, et al.. (2016). First Experience with Chemokine Receptor CXCR4–Targeted PET Imaging of Patients with Solid Cancers. Journal of Nuclear Medicine. 57(5). 741–746. 109 indexed citations
20.
Teodorczyk, Marcin, Susanne Kleber, Damian Wollny, et al.. (2015). CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma. Cell Death and Differentiation. 22(7). 1192–1202. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julien Lazarovici Breakdown of academic impact, for papers by Deniz Şahin Breakdown of academic impact, for papers by Siobhan Ng Breakdown of academic impact, for papers by Dave Yamauchi Breakdown of academic impact, for papers by Guillaume Manson Breakdown of academic impact, for papers by Stefan Habringer Breakdown of academic impact, for papers by Vittorio Silingardi Breakdown of academic impact, for papers by Khalil Saleh Breakdown of academic impact, for papers by Kensei Nakata Breakdown of academic impact, for papers by Joyce Varughese
Rankless by CCL
2026